Asthma and COVID-19 : lessons learned and questions that remain
INTRODUCTION: Asthma is one of the most common chronic diseases worldwide. As a disease of the respiratory tract, the site of entry for the SARS-CoV-2 virus, there may be an important interplay between asthma and COVID-19 disease.
AREAS COVERED: We report asthma prevalence among hospitalized cohorts with COVID-19. Those with non-allergic and severe asthma may be at increased risk of a worsened clinical outcome from COVID-19 infection. We explore the epidemiology of asthma as a risk factor for the severity of COVID-19 infection. We then consider the role COVID-19 may play in leading to exacerbations of asthma. The impact of asthma endotype on outcome is discussed. Lastly, we address the safety of common asthma therapeutics. A literature search was performed with relevant terms for each of the sections of the review using PubMed, Google Scholar, and Medline.
EXPERT OPINION: Asthma diagnosis may be a risk factor for severe COVID-19 especially for those with severe disease or nonallergic phenotypes. COVID-19 does not appear to provoke asthma exacerbations and asthma therapeutics should be continued for patients with exposure to COVID-19. Clearly much regarding this topic remains unknown and we identify some key questions that may be of interest for future researchers.[Figure: see text].
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Expert review of respiratory medicine - 15(2021), 11 vom: 12. Nov., Seite 1377-1386 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Howell, Daniel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Asthma |
|---|
| Anmerkungen: |
Date Completed 29.10.2021 Date Revised 29.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/17476348.2021.1985763 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331122901 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331122901 | ||
| 003 | DE-627 | ||
| 005 | 20231225212752.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17476348.2021.1985763 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1103.xml |
| 035 | |a (DE-627)NLM331122901 | ||
| 035 | |a (NLM)34570678 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Howell, Daniel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Asthma and COVID-19 |b lessons learned and questions that remain |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.10.2021 | ||
| 500 | |a Date Revised 29.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Asthma is one of the most common chronic diseases worldwide. As a disease of the respiratory tract, the site of entry for the SARS-CoV-2 virus, there may be an important interplay between asthma and COVID-19 disease | ||
| 520 | |a AREAS COVERED: We report asthma prevalence among hospitalized cohorts with COVID-19. Those with non-allergic and severe asthma may be at increased risk of a worsened clinical outcome from COVID-19 infection. We explore the epidemiology of asthma as a risk factor for the severity of COVID-19 infection. We then consider the role COVID-19 may play in leading to exacerbations of asthma. The impact of asthma endotype on outcome is discussed. Lastly, we address the safety of common asthma therapeutics. A literature search was performed with relevant terms for each of the sections of the review using PubMed, Google Scholar, and Medline | ||
| 520 | |a EXPERT OPINION: Asthma diagnosis may be a risk factor for severe COVID-19 especially for those with severe disease or nonallergic phenotypes. COVID-19 does not appear to provoke asthma exacerbations and asthma therapeutics should be continued for patients with exposure to COVID-19. Clearly much regarding this topic remains unknown and we identify some key questions that may be of interest for future researchers.[Figure: see text] | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a asthma | |
| 650 | 4 | |a asthma epidemiology | |
| 650 | 4 | |a asthma genetics | |
| 650 | 4 | |a asthma treatment | |
| 700 | 1 | |a Verma, Hannah |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Kam Sing |e verfasserin |4 aut | |
| 700 | 1 | |a Narasimhan, Bharat |e verfasserin |4 aut | |
| 700 | 1 | |a Steiger, David |e verfasserin |4 aut | |
| 700 | 1 | |a Rogers, Linda |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of respiratory medicine |d 2007 |g 15(2021), 11 vom: 12. Nov., Seite 1377-1386 |w (DE-627)NLM190765666 |x 1747-6356 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2021 |g number:11 |g day:12 |g month:11 |g pages:1377-1386 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17476348.2021.1985763 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2021 |e 11 |b 12 |c 11 |h 1377-1386 | ||